Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01978587 · ClinicalTrials.gov registry record · Phase 1
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease
A Phase 1 study of Anemia in Chronic Kidney Disease, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01978587: Completed Phase 1 study of Anemia in Chronic Kidney Disease, sponsored by Akros Pharma.
NCT01978587 is a Phase 1 study of Anemia in Chronic Kidney Disease that has completed, run by Akros Pharma. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01978587, a Phase 1 study of Anemia in Chronic Kidney Disease, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis
Conditions Studied
Interventions
- DRUG JTZ-951
Study Locations (1)
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
What the finished NCT01978587 record still lists
NCT01978587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Anemia in Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which JTZ-951 is the first listed.
NCT01978587 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01978587 about?
NCT01978587 is a clinical study titled "Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease". The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis
What is the current status of trial NCT01978587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-10. Estimated completion is 2014-01.
What conditions does trial NCT01978587 study?
This clinical trial studies the following conditions: Anemia in Chronic Kidney Disease.
What interventions are being tested in trial NCT01978587?
The interventions under investigation include: JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT01978587?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01978587 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01978587's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia